Virtual Library
Start Your Search
Wen-Fang Tang
Author of
-
+
P2.14 - Targeted Therapy (ID 183)
- Event: WCLC 2019
- Type: Poster Viewing in the Exhibit Hall
- Track: Targeted Therapy
- Presentations: 1
- Now Available
- Moderators:
- Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
-
+
P2.14-36 - Identification of Genomic Features in Tumor-Derived Organoids from Resectable NSCLC (Now Available) (ID 1275)
10:15 - 18:15 | Author(s): Wen-Fang Tang
- Abstract
Background
Patient-derived tumor organoids (PDOs) have recently emerged as robust preclinical models. However, few studies were published on lung cancer organoid. This study aims to describe the genomic characteristics of PDOs as a disease model of NSCLC.
Method
Samples from resected tumors were collected for organoid culture. DNA was extracted from tumor, organoids and matched PBLs samples and sequenced with whole-exome sequencing.
Result
Seven pts were enrolled, including six LUAD (86 %) and one LUSC (14 %). A total of 1625 somatic mutations were detected in tumors. TP53 (71%), EGFR (43%), and KRAS (29%) mutated most frequently in this cohort, and occurred with frequencies of (57%), (43%) and (29%) in matched PDOs. Based on gene catalog related to lung cancer, the median consistency between tumor and organoid was 87 % (0% ~ 100%). Sample purity was significantly positively related to the variant allele frequency (r=0.82, P=0.0005), and may result in the inconsistence between paired samples. Besides, number of driver gene showed no difference between first- and second-generation organoids.
This study firstly revealed genomic landscape of NSCLC organoid. In spite of heterogeneity, driver mutations presented high consistency between PDOs and paired tumor. Further study is continuing to evaluate outcomes from patients enrolled.